Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.

Positive

• Focus on novel peptide-based therapeutics for significant health issues.
• Lead product candidate pemvidutide (ALT-801) targets obesity and liver diseases.

Negative

• None.

GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.

Conference Call Information:

Date:	Thursday, May 12
Time:	8:30 am Eastern Time
Domestic Dial-in:	(800) 225-9448
International Dial-in:	(203) 518-9708
Conference ID:	ALTQ122
Webcast:	https://edge.media-server.com/mmc/p/j5i9f735

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

When will Altimmune report its first quarter 2022 financial results?

Altimmune will report its first quarter 2022 financial results on May 12, 2022.

What time is the Altimmune conference call scheduled for?

The Altimmune conference call is scheduled for 8:30 AM ET on May 12, 2022.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide (ALT-801), developed for obesity and NASH.

What therapeutic area is Altimmune focusing on?

Altimmune focuses on developing treatments for obesity, liver diseases, and chronic hepatitis B.